| Date | Title | Description | Source |
| 05.04.2023 | Protagonist Therapeutics Announces Pricing of $100 Million P... | NEWARK, CA / ACCESSWIRE / April 4, 2023 / Protagonist Therapeutics PTGX ("Protagonist" or ... | einpresswi... |
| 04.04.2023 | Protagonist Therapeutics Announces Pricing of $100 Million P... | - | accesswire... |
| 10.08.2021 | Protagonist Therapeutics Announces Resolution of Contract Di... |
NEWARK, Calif., Aug. 10, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("... | prnewswire... |
| 28.07.2021 | Protagonist Therapeutics Announces Amendment of Agreement wi... |
NEWARK, Calif., July 28, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) ("... | prnewswire... |
| 21.06.2021 | PROTAGONIST THERAPEUTICS, INC.
Protagonist Therapeutics Inc... | Protagonist Therapeutics, Inc. (Nasdaq:PTGX), a clinical stage biopharmaceutical company, today anno... | marketscre... |
| 18.06.2021 | PROTAGONIST THERAPEUTICS, INC.
Protagonist Therapeutics, In... | NEWARK, Calif., June 18, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX), a clinic... | marketscre... |
| 18.06.2021 | Protagonist Therapeutics, Inc. Announces Closing of $132.2 M... |
NEWARK, Calif., June 18, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX), a clin... | prnewswire... |
| 16.06.2021 | PROTAGONIST THERAPEUTICS, INC.
Protagonist Therapeutics : A... | NEWARK, Calif., June 15, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clini... | marketscre... |
| 15.06.2021 | Protagonist Therapeutics Announces Pricing of $115 Million U... |
NEWARK, Calif., June 15, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a cli... | prnewswire... |
| 14.06.2021 | Protagonist Therapeutics Announces Proposed Public Offering ... |
NEWARK, Calif., June 14, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX), a clin... | prnewswire... |
| 11.06.2021 | Protagonist Therapeutics Announces Updated Phase 2 Data Supp... |
NEWARK, Calif., June 11, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq:PTGX) ("Protag... | prnewswire... |
| 03.06.2021 | Protagonist Therapeutics Receives FDA Breakthrough Therapy D... |
NEWARK, Calif., June 3, 2021 /PRNewswire/ -- Protagonist Therapeutics ("Protagonist" or ... | prnewswire... |
| 24.05.2021 | Protagonist Therapeutics Announces First Subject Dosed in Ph... |
NEWARK, Calif., May 24, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today an... | prnewswire... |
| 12.05.2021 | Protagonist Therapeutics Announces Presentation of Updated R... |
NEWARK, Calif., May 12, 2021 /PRNewswire/ -- Protagonist Therapeutics ("Protagonist" or ... | prnewswire... |
| 27.04.2021 | Protagonist Therapeutics Completes Enrollment for Phase 2 St... |
NEWARK, Calif., April 27, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. ("Protagonist&q... | prnewswire... |
| 22.03.2021 | Protagonist Announces Plans to Initiate a Global Phase 3 Stu... |
NEWARK, Calif., March 22, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Prot... | prnewswire... |
| 10.03.2021 | Protagonist Therapeutics Reports Fourth Quarter and Full Yea... |
NEWARK, Calif., March 10, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. ("Protagonist&q... | prnewswire... |
| 16.12.2020 | Protagonist Therapeutics Announces First Subject Dosed in Ph... |
NEWARK, Calif., Dec. 16, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today a... | prnewswire... |
| 15.12.2020 | Protagonist Therapeutics, Inc. Announces Closing of $115 Mil... |
NEWARK, Calif., Dec. 15, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a cli... | prnewswire... |
| 21.10.2020 | Protagonist Therapeutics Receives Orphan Drug Designation fr... |
NEWARK, Calif., Oct. 21, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today a... | prnewswire... |
| 07.08.2018 | Protagonist Therapeutics Secures $22M in Equity Financing | Protagonist Therapeutics, Inc. (Nasdaq:PTGX), a Newark, Calif.-based biopharmaceutical company lever... | finsmes.co... |
| 09.04.2018 | The biotech, digital health VC to know | Julie Papanek Grant, a partner at Silicon Valley healthcare and tech VC firm Canaan Partners, has ma... | medcitynew... |
| 07.06.2017 | How a company could disrupt billion-dollar drug markets with... | Reuters/Brian Snyder
An injection
Advertisement
Many of the powerful drugs used to treat autoimmu... | businessin... |
| 19.07.2015 | Easy pill to swallow: Aussie biotech startup raises $40 mill... | A biotech startup spun out of the University of Queensland has raised $40 million to help develop a ... | smartcompa... |
| 17.07.2015 | Daily funding roundup - July 17, 2015 | Protagonist Therapeutics bagged $40M; Upstart raised $35M; Courtagen secured $20M
CredSimple, a sta... | vator.tv/n... |
| 16.07.2015 | Protagonist snags $40M to bring next-gen IBD drugs to clinic | GI disease is the low-hanging fruit at present, but Protagonist is envisioning broader applications ... | medcitynew... |
| 16.07.2015 | Protagonist Therapeutics Raises $40 Million Series C Financi... | - | jnjinnovat... |
| 16.07.2015 | Protagonist Therapeutics lands $40M round for an oral peptid... | Protagonist CEO Dinesh Patel
It's not easy creating an oral peptide drug aimed at irritable bowel d... | fiercebiot... |
| 19.09.2013 | Protagonist Therapeutics Expands Series B Financing to $18 M... | - | jnjinnovat... |
| 04.06.2013 | Protagonist Pulls in $14M, Led by J&J, For Peptide Pills | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Not many companies know how to mak... | xconomy.co... |
| 04.06.2013 | Protagonist Therapeutics Raises $14 Million in Series B Vent... | - | jnjinnovat... |
| 04.06.2013 | Protagonist Therapeutics Completes $14M Series B Venture Fin... | Protagonist Therapeutics, Inc., a U.S.-based biotechnology company, completed a $14m Series B ventur... | finsmes.co... |
| 04.06.2013 | Protagonist Therapeutics Raises $14M Series B |
MENLO PARK, CA, The financing, led by new investor Johnson & Johnson Development Corporation (... | vcnewsdail... |
| 04.06.2013 | Protagonist Therapeutics Raises $14 Million in Series B Vent... | Protagonist Therapeutics Raises $14 Million in Series B Venture Financing
Menlo Park, Calif. (June ... | fiercebiot... |
| - | Protagonist snags $40M to bring next-gen IBD drugs to clinic | The targeted therapy approach to gastrointestinal diseases like ulcerative colitis and inflammatory ... | medcitynew... |
| - | The biotech, digital health VC to know | There are lists featuring women of influence.
There are 40 under 40 rankings.
Julie Papanek Grant,... | medcitynew... |
